P2X7 receptors mediate resistance to toxin-induced cell lysis by Schönauer, Roman et al.
1 
 
P2X7 receptors mediate resistance to toxin-induced cell lysis 
 
Roman Schoenauer1, Alexander P. Atanassoff1, Heidi Wolfmeier1, Pablo Pelegrin2, 
Eduard B. Babiychuk1, Annette Draeger1,* 
1 Institute of Anatomy, University of Bern, Bern, Switzerland 
2 Inflammation and Experimental Surgery Research, University Hospital Virgen de la 
Arrixaca- FFIS, Murcia, Spain 
 
Running title: P2X7 receptors mediate resistance to toxin-induced cell lysis 
 
Keywords: P2X7, plasmalemma, blebbing, calcium, lysis, annexin                                                                         
ABSTRACT  
In the majority of cells, the integrity of the plasmalemma is recurrently compromised by 
mechanical or chemical stress. Serum complement or bacterial pore-forming toxins can 
perforate the plasma membrane provoking uncontrolled Ca2+ influx, loss of cytoplasmic 
constituents and cell lysis. Plasmalemmal blebbing has previously been shown to protect 
cells against bacterial pore-forming toxins. The activation of the P2X7 receptor (P2X7R), 
an ATP-gated trimeric membrane cation channel, triggers Ca2+ influx and induces 
blebbing. We have investigated the role of the P2X7R as a regulator of plasmalemmal 
protection after toxin-induced membrane perforation caused by bacterial streptolysin O 
(SLO). 
Our results show that the expression and activation of the P2X7R furnishes cells with an 
increased chance of surviving attacks by SLO. This protective effect can not only be 
demonstrated in human embryonic kidney 293 (HEK) cells transfected with the P2X7R, but 
also in human mast cells (HMC-1), which express the receptor endogenously. In addition, 
this effect is abolished by treatment with blebbistatin or A-438079, a selective P2X7R 
antagonist. Thus blebbing, which is elicited by the ATP-mediated, paracrine activation of 
the P2X7R, is part of a cellular non-immune defense mechanism. It pre-empts 
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plasmalemmal damage and promotes cellular survival. This mechanism is of considerable 
importance for cells of the immune system which carry the P2X7R and which are 
specifically exposed to toxin attacks. 
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P2X7R, P2X7 receptor; RT, room temperature; SLO, streptolysin O 
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1. INTRODUCTION 
Serum complement or bacterial pore-forming toxins perforate the plasma membrane of a 
host cell and cause influx of extracellular - and efflux of cytoplasmic components, which 
might lead to cell death [1-4]. It is thus not surprising that eukaryotic cells have developed 
membrane repair mechanisms and adapted them to suit the nature and severity of 
plasmalemmal injury [5-8]. A breakdown of the Ca2+ concentration gradient between 
cytoplasm and extracellular milieu serves as an indicator of plasmalemmal disruption and 
acts as molecular guidance for the intracellular repair machinery. Intracellular [Ca2+] 
elevations are recognized by Ca2+ sensors such as proteins of the annexin family, which 
bind Ca2+-dependently to negatively-charged phospholipids [9] and have been ascribed a 
role in plasmalemmal repair [10-13].  
Blebbing - a temporary detachment of the lipid bilayer from the submembranous 
cytoskeleton - is considered to be an early sign of intracellular Ca2+ elevation, which 
indicates imminent or incipient membrane injury [14]. We have recently proposed blebbing 
to be a damage-control mechanism, which is triggered after the failure of plasmalemmal 
resealing [15]. The ability to bleb provides a clear benefit of survival for a cell confronted 
with attacks on its plasmalemma by pore-forming toxins [15].  
Since P2X7R activation is associated with an increase in membrane blebbing [16], we 
have investigated the role of this receptor as a molecular regulator of plasma membrane 
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protection after plasmalemmal perforation caused by the bacterial toxin SLO. The 
ionotropic P2X7R has two transmembrane domains; intracellular NH2- and COOH-termini 
and forms a homotrimer [17]. It is ubiquitously expressed, with high levels in immune cells 
and exists as a multiprotein complex, including the non-muscle myosin heavy chains and 
other cytoskeletal elements [18, 19]. The activation of the P2X7R by extracellular ATP 
opens a cationic channel which gradually dilates to a larger pore [20-22]. It is itself subject 
to regulation by numerous polymorphic variants and isoforms which increase or decrease 
its efficiency [23]. In macrophages primed by lipopolysaccharide, channel opening is 
additionally associated with the secretion of pro-inflammatory cytokines IL-1β [24, 25] and 
IL-18 [26, 27]. P2X7R activation is followed by downstream effects such as blebbing [28, 
29], microvesicle shedding [30, 31], cell fusion [32], proliferation [33] and eventually cell 
death [34]. Furthermore, in the absence of ATP, P2X7R plays a role in recognition and 
phagocytosis of foreign particles [35, 36]. 
We demonstrate that the expression of the P2X7R confers resistance to the attack by 
bacterial pore-forming toxins. This protective effect can be increased by activation of the 
P2X7R with ATP and is abolished by pretreatment with blebbistatin or A-438079, a 
selective P2X7R antagonist. We further suggest that the paracrine activation of this 
receptor by ATP, released by damaged neighbouring cells, initiates blebbing and thus 
induces resistance to toxin-induced cell lysis. Blebbing is a characteristic feature of injured 
cells. It is thus conceivable that cells – in particular within inflammatory foci – use this ATP-
triggered, P2X7R-mediated warning system to alert their neighbours to an approaching 
wave of bacterial toxins.    
 
 
2. MATERIALS AND METHODS 
 
2.1. Cell culture 
HEK cells were maintained in DMEM (Dulbecco’s modified Eagle’s medium), containing 2 
mM glutamax, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal calf serum (FCS) 
and were transfected as described [11, 37]. HEK cells stably transfected with the rat 
P2X7R (HEKrtP2X7) or the human P2X7R (HEKhuP2X7) [38] were cultured in DMEM/F12 
medium supplemented with 2 mM glutamax, G418 (300 µg/ml), 2 mM MgCl2 and 10% 
FCS. HMC-1 were cultured in IMDM with 10% FCS, 100 U/ml penicillin and 100 μg/ml 
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streptomycin as described [39]. All cells were grown in 5% CO2 at 37°C in a humidified 
incubator. For the viability experiments, the cells were challenged with 750 U/ml SLO from 
Streptococcus pyogenes (Sigma-Aldrich, Buchs, Switzerland) in Tyrode’s buffer (140 mM 
NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES; pH = 7.4) containing 2.5 
mM CaCl2 or 1 mM EGTA (for the experiment without extracellular calcium) for 15 min at 
room temperature (RT). Cell viability was quantified by the cell health indicator 
alamarBlue® following the manufacturer instructions (Life Technologies, Carlsbad, USA 
[40]). To inhibit P2X7R-specific ATP stimulation, the cells were incubated with 1 µM or 10 
µM A-438079 (Sigma-Aldrich, Buchs, Switzerland) for 15 min at RT. 
 
  
2.2. Expression of annexins as fusions with fluorescent proteins 
 
The coding sequences of annexin A1 and A2 were cloned into the Living Colors 
Fluorescent protein vectors pEGFP-N1 or pEYFP-N1 (Clontech, Saint-Germain-en-Laye, 
France) following PCR amplification from human bladder smooth muscle cDNA. The 
fluorescent protein was attached to the C-terminus of the annexins, which has been shown 
not to affect the protein function [41]. The oligonucleotide pairs used for PCR correspond 
to the N-termini (forward) and C-termini (reverse, lacking the stop codon) of annexins and 
contain appropriate restriction sites to allow the in-frame cloning with fluorescent proteins. 
For annexin A1, 5’-TTTAAGCTAGCGATGGCAATGGTATCAGATTCCTC-3’ forward and   
3’TTATTCTGCAGGTTTCCTCCAAACAGAGCCAC-5’ reverse.  
For annexin A2, 5’-AATATAGCTAGCATGTCTACTGTTCACGAAATCCTG-3’ forward and 
5’ATAAACTCGAGTTAGTATAGGCTTTGACAGAC-3’ reverse. 
 
 
2.3. Imaging 
 
Glass coverslips with annexin-expressing HEK cells were mounted in a perfusion chamber 
at RT in Tyrode's buffer containing 2.5 mM CaCl2. To induce blebbing, the ATP analogue 
2’(3’)- O-(4-Benzoylbenzoyl)ATP (BzATP) was added to the cells at concentrations 
between 10 µM and 100 µM (in Tyrode’s buffer). Cell lysis was monitored by irreversible 
elevation of intracellular [Ca2+] above 20 µM using permanent plasmalemmal translocation 
of annexin A1 as a read-out [15]. Cells were challenged with 750 U/ml SLO in Tyrode’s 
buffer for 15 min at RT. When indicated, the cells were pretreated with blebbistatin (100 
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µM, 30 min) and/or ATP (30µM, 10-15 min) before the addition of SLO. The fluorescence 
was recorded in an Axiovert 200M microscope with a laser scanning module LSM 510 
META (Carl Zeiss AG, Feldbach, Switzerland) using a 63x oil immersion lens. The images 
were analyzed using the ‘Zeiss LSM Image examiner' software package (Carl Zeiss AG). 
To determine the percentage of lysis, the number of cells with annexin A1 translocation 
was divided by the total cell number [15]. Transient plasmalemmal translocations of 
fluorescently-labeled annexin A2 were used to monitor elevations of intracellular Ca2+ in 
the low micromolar range [11, 42]. 
Numerical data are expressed as mean values together with the standard error. The 
statistical analyses were performed using GraphPad Prism 5.04 and Microsoft Excel 2010. 
The level of significance was set at p<0.05. Significant differences are marked with 
asterisks. 
 
 
2.4. Western blotting 
HEK, HEKrtP2X7 and HEKhuP2X7 cells were resuspended in SDS sample buffer (200 
mM Tris–HCl, 40 mM EGTA, pH 7, 3.1% SDS, 7.7% β-mercaptoethanol, 13.4% glycerol 
and 60 µg/ml of bromophenol blue) and boiled for 1 min. Samples were run on 8% SDS-
polyacrylamide minigels together with a molecular weight marker (Page Ruler Prestained, 
Thermo Scientific, Erembodegem, Belgium). Equal amounts of protein were loaded for the 
different protein extracts as estimated by a test gel. Blotting was carried out overnight onto 
a PVDF membrane (Millipore AG, Zug, Switzerland). Unspecific binding sites were blocked 
with 4% non-fat dry milk in low salt buffer (0.9% NaCl, 10 mM Tris-Base, 0.1% Tween 20) 
for 1 h at RT. Primary antibodies (polyclonal rabbit-anti-P2X7, Alomone Labs, Jerusalem, 
Israel) were diluted in low salt buffer supplemented with 2% non-fat milk powder and 
incubated for 1 h at RT. The blot was washed 3 times with low salt buffer for 10 min. 
Secondary antibodies (HRP-donkey-anti-rabbit IgG, GE Healthcare, Glattbrugg, 
Switzerland) were diluted in low salt buffer supplemented with 2% non-fat milk powder and 
incubated for 45 min at RT. Finally, the blot was washed again 3 times with low salt buffer 
for 10 min. Chemiluminescence reaction was performed using Western Bright ECL from 
Advansta (Menlo Park, CA, USA) and the signal was detected by a Fusion FX imaging 
system (Vilber Lourmat, Marne-la-Vallée, France). 
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3. RESULTS 
 
In order to investigate P2X7R function in plasmalemmal repair, we initially applied a well 
characterized model system (HEK cells), in which blebbing has previously been 
associated with increased survival [15].  We confirmed that the transcription (Figure 1A) 
and protein expression (Figure 1B) of P2X7R occurred in HEK cells stably transfected with 
the P2X7R gene, but not in control cells. Immunostaining with antibodies against the 
P2X7R demonstrated that it was localized to the plasmalemma, as previously described, 
whereas untransfected HEK cells were devoid of signal (Figure 1C). 
The activation of a functional P2X7R leads to an increase in [Ca2+], followed by blebbing 
[43, 44]. Therefore, the functionality of the P2X7R in stably transfected HEK cells was 
established by stimulation with increasing concentrations of BzATP and by simultaneous 
monitoring of blebbing activity and [Ca2+] by Ca2+-dependent plasmalemmal translocation 
of fluorescently labeled annexin A2 [11].  
HEKrtP2X7 cells responded to increasing concentrations of BzATP by an increased 
plasmalemmal blebbing (Figure 2A and Supplementary Movie 1). After stimulation with 10 
µM BzATP, 2.4±1.8% of the cells blebbed, whereas at 30 µM BzATP, ~ 50% of the cells 
displayed blebbing during 1 h of treatment. At a concentration of 100 µM BzATP, almost all 
cells blebbed (98.6±1.4%; 450 cells on 30 slides). 
Annexin A2 reversibly translocates between the cytoplasm and the plasmalemma at low 
micromolar [Ca2+]i [42]. In non-stimulated cells, annexin A2 localizes within the cytoplasm 
[11]; this pattern was not altered by the expression of the P2X7R. Blebbing closely 
correlated with annexin A2 membrane translocation, confirming Ca2+ influx through the 
opened P2X7 channel after stimulation with BzATP (Figure 2B). Stimulation with 30 µM 
BzATP led to increased blebbing (Figure 2C) and plasmalemmal translocation of annexin 
A2 (Figure 2D) in 64.5±8.1% of cells (495 cells on 33 slides).  
In order to determine the role of the P2X7R in cellular survival, toxin-induced lysis was 
analyzed by monitoring irreversible membrane translocation of YFP-annexin A1 ( [Ca2+]i –
elevation above 20 µM) [15]. Figure 3A shows that the expression of the P2X7R alone 
confers resistance against SLO toxicity. HEKrtP2X7 cells showed a significantly lower 
amount of SLO-induced lysis (59.5%±6.4%, t-test: P<0.001; 147 cells on 11 slides) 
compared to the wild-type cells (100%±4.8%, 187 cells on 13 slides). As expected, the 
P2X7R stimulation with ATP prior to toxin incubation led to an additional reduction of lysis 
(Figure 3B; 24.4%±7.7%, t-test: P<0.01, 277 cells on 14 slides). Representative confocal 
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micrographs depict the extent of annexin A1 translocation during the experimental 
conditions described above (Figure 3C). 
To elucidate the role of Ca2+ in the protective effect of the P2X7R, we performed 
alamarBlue® cell viability assays [40]. In the presence of extracellular Ca2+, an increased 
viability was observed in HEKrtP2X7 cells compared to non-transfected HEK cells (Figure 
3D). Correspondingly, we could detect significantly more blebbing in HEKrtP2X7 cells 
compared to HEK cells (44.5±9.9% versus 27.1±4.7%) after SLO-treatment (Figure 3E). 
Such protective effect was lacking in the absence of extracellular Ca2+ and the viability 
after treatment with SLO at Ca2+-free conditions was drastically reduced in both cell types.  
Our data demonstrate that the P2X7R has a protective effect, which is dependent on the 
extracellular [Ca2+], even without activation by ATP. Ca2+ ions can enter the cells through 
the SLO pores and trigger blebbing by activating contraction of myosin II [46]. The 
increase in blebbing in HEKrtP2X7 cells compared to HEK cells even without stimulation 
by ATP may be a consequence of the increased ability of the endoplasmatic reticulum (ER) 
to accumulate, store and release Ca2+ [47]. Consequently, the Ca2+ influx via toxin pores 
might potentiate Ca2+ release from the ER, leading to a larger increase in cytosolic [Ca2+] 
in P2X7 transfected cells resulting in stronger blebbing. 
We next investigated whether membrane blebbing was responsible for the protection 
against lysis. Blebbing - and its concomitant positive effect on cellular survival mediated by 
the P2X7R - was inhibited by pretreatment with blebbistatin (Figure 4A; 513 cells on 27 
slides; Figure 4B), an agent that is known to interact with non-muscle myosin II and to 
inhibit blebbing [48].  
To determine if ATP is a P2X7R-specific mediator of this process, we treated HEKrtP2X7 
cells with A-438079, a selective P2X7R antagonist, which reversibly blocks rat and human 
P2X7R and inhibits BzATP induced IL-1β release as well as pore formation [49]. 
Pretreatment with A-438079 before the incubation with ATP (30 µM) and SLO treatment, 
led to a complete abolishment of the ATP-mediated protective effect (Figure 5A; 33 
measurements in 3 independent AlamarBlue® assays).  
The physiological significance of our findings were emphasized in experiments with HMC-
1, which express the P2X7R endogenously [50]. Viability was significantly increased after 
pretreatment of the mast cells with ATP prior to toxin exposure (Figure 5B; from 17.7±1.3% 
to 32.1±1.6%; 34 measurements in 3 independent assays) and abolished by pretreatment 
with A-438079. 
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4. DISCUSSION 
The P2X7R has been proposed to function as a regulator of inflammation [51]. In systemic 
illnesses such as rheumatoid arthritis, the activation of the P2X7R is associated with an 
increase in the secretion of proinflammatory cytokines and an exacerbation of the disease 
[52]. Its prolonged activation leads to apoptotic cell death [53] and its absence has been 
linked to a diminished output of inflammatory mediators such as IL-1 [54]. ATP is 
considered a physiological ligand of the P2X7R, which in vivo is released from viable or 
dying cells or from degranulating platelets [55-57]. In view of its effect on neighbouring 
cells, ATP has been identified as an endogenous danger signal with potentially detrimental 
effects when it is released into the extracellular space after tissue damage [58].  
Numerous studies have addressed the frequently deleterious consequences for an 
organism, which is flooded with proinflammatory cytokines following P2X7R activation [52, 
58]. Conversely, the absence or loss-of-function of the P2X7R has been shown to diminish 
cellular host defenses against pathogens such as Chlamydia [59] or Toxoplasma gondii 
[60]. 
Our study addresses the role of P2X7R activation in the survival of cells subjected to an 
attack by bacterial toxins. Exposed to an often unfavorable environment and threatened by 
the exposure to bacterial toxins, cellular survival is critically dependent on an early warning 
system in combination with efficient plasmalemmal repair. 
Plasmalemmal repair can be achieved by different Ca2+-dependent mechanisms: 
eukaryotic cells are capable of patching injured regions with internal membranes 
transported to the surface of the cell by exocytosis [5] or of resealing the plasma 
membrane by endocytosis of the damaged sites [6, 61]. Microparticle shedding has been 
shown to play a role in the quarantining and elimination of injured plasmalemmal regions 
[8, 62]. 
Previous studies have associated enhanced P2X7R activity with plasmalemmal blebbing 
[21, 63] and microvesicle shedding [30] as well as with the death of injured cells [14, 64]. 
In addition, blebs play also a role in cellular migration [46, 65, 66]. We have recently 
proposed that blebs confer resistance to toxin-induced plasmalemmal injury by acting as a 
trap for the damaged membrane region, which is sealed off from the cell body [15].  
Proteins of the annexin family are able to sense elevated [Ca2+]i [42]. In the presence of 
Ca2+, annexin A1 aggregates and fuses biological membranes [9, 67-69]. Exposed to a 
strong flux of Ca2+ in the vicinity of a toxin pore, annexin A1 binds to the plasmalemma 
within the bleb and cross-links the adjacent membranes of its slender neck, thus forming a 
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plug that creates two separate compartments. This process enables the cell to repair its 
plasmalemma within the bleb without endangering the cell body. After membrane integrity 
has been restored and Ca2+ homeostasis has been re-established, annexin A1 
translocates back to the cytoplasm thereby dissolving the plug [13]. 
Stimulation of the P2X7R (by ATP or its analogue BzATP) leads to the opening of a cation 
channel [21] and Ca2+ influx, which initiates blebbing [28] and microparticle release [30]. 
Our data show that the expression of the P2X7R alone improves the survival of cells 
during attacks by the pore-forming bacterial toxin SLO. This protective effect is even more 
pronounced if the receptor is stimulated with its physiological ligand ATP prior to toxin 
exposure. In addition, this effect can be inhibited by pretreatment with blebbistatin or a 
specific P2X7R antagonist. 
 
 
5. CONCLUSIONS 
Plasmalemmal blebbing constitutes an intricate cellular defense system: on the one hand, 
blebbing allows the cell to isolate the damaged plasmalemmal segment and protects the 
cell body from further injury by restricting the elevated intracellular [Ca2+] to the blebs [15], 
on the other hand, the release of ATP from the injured cell acts as a paracrine stimulus 
and induces blebbing by activating the P2X7 receptors of cells in the vicinity (Figure 6). 
Our study underlines the important role of P2X7R-induced blebbing as part of a non-
immune defense mechanism against bacterial pore-forming toxins. Since the P2X7R is 
particularly prevalent in cells of the immune system [70], this mechanism warns and 
shields those cells, which are in the first line of toxin attacks. 
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FIGURE LEGENDS 
 
Figure 1. Expression and localization of the P2X7R in stably transfected HEK cells. (A) 
qRT-PCR analysis of P2X7R expression confirms its presence only in the stably 
transfected cell line (rtP2X7). (B) Western blot analysis of HEK (1-2), HEKrtP2X7 (3-4) and 
HEKhuP2X7 (5-6) cells shows the P2X7R to be present only in the transfected cell lines 
(column 3-6). β-actin was used as loading control. (C) A confocal micrograph of 
HEKrtP2X7 cells (left picture) immunolabeled with an antibody against the P2X7R (green) 
and DAPI (red) reveals the plasmalemmal localization of the receptor. HEK cells (right 
picture) do not show any membrane labeling. Scale bar = 10 µm. 
 
Figure 2. Blebbing and annexin A2 translocation are induced in HEKrtP2X7 cells treated 
with BzATP. (A) Stimulation of the P2X7R by BzATP induces blebbing in a concentration 
dependent manner (N = 30). (B) Plasmalemmal translocation of annexin A2 after BzATP 
treatment (N = 33). Asterisks = significant difference compared to the results from the 100 
µM experiment in each graph. (C) Representative confocal micrographs show GFP-
transfected HEKrtP2X7 cells before (upper picture) and after stimulation with 100 µM 
BzATP (lower picture), where blebbing is clearly visible. (D) The cytoplasmic localization of 
annexin A2-GFP (Anx2-GFP) in transfected HEKrtP2X7 cells before stimulation with 100 
µM BzATP (upper picture) and its membrane translocation after stimulation with 100 µM 
BzATP (lower picture). Treatments were performed for 1 h at RT. Scale bar = 20 µm. 
 
Figure 3. The expression of the P2X7R in HEK cells confers resistance against SLO 
treatment. Lysis was analyzed by the annexin A1 translocation assay. (A) HEKrtP2X7 cells 
treated with SLO for 15 min show a significantly lower amount of lysis compared to HEK 
cells (HEK: N = 22, HEKrtP2X7: N = 26 per experimental group; t-test: P<0.001). (B) ATP 
stimulation protects HEKrtP2X7 cells against lysis by SLO. Pretreatment of HEKrtP2X7 
cells with 30 µM ATP for 10 min leads to a significant additional reduction of lysis. N = 6 
per experimental group, t-test: P<0.01. (C) Confocal micrographs of HEK and HEKrtP2X7 
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cells transfected with YFP-labeled annexin A1 after SLO treatment for 15 min (HEK = HEK 
cells; P2X7 = HEKrtP2X7 cells; +ATP = 30 µM ATP pretreatment for 15 min). Scale bar = 
20 µm. (D) AlamarBlue® viability assays of HEK and HEKrtP2X7 cells after SLO treatment 
for 15 min without extracellular calcium (no [Ca2+]) and with 2.5 mM extracellular calcium 
(2.5 mM [Ca2+]). (E) Percentage of blebbing during incubation with SLO for 15 min in HEK 
and HEKrtP2X7 cells. The transfected cells show significantly more blebbing. The 
extracellular calcium concentration was adjusted to 2.5 mM in (A)-(C) and (E). All 
treatments were performed at RT. Asterisks = significant differences compared to the left 
bars. 
 
Figure 4. Blebbistatin treatment abolishes the protective effect of ATP stimulation during 
toxin attack by SLO. (A) In HEKrtP2X7 cells, pretreatment with blebbistatin (100 µM) for 30 
min leads to a reversal of the protective effect in cell lysis caused by treatment with ATP 
(30 µM, 15 min). Ctrl: 45 min incubation with Tyrode’s buffer; ATP: 30 min Tyrode’s buffer 
+ 15 min ATP (30 µM) in Tyrode’s buffer; bleb: 30 min incubation with blebbistatin (100 
µM) + 15 min ATP (30 µM), both in Tyrode’s buffer with 2.5 mM [Ca2+]. All treatments were 
followed by incubation with SLO for 15 min. N = 9 per experimental goup, t-test: P<0.01 
(ctrl - ATP); P<0.05 (ATP - bleb). (B) Confocal micrographs of HEKrtP2X7 cells transfected 
with YFP-labeled annexin A1 after SLO treatment (ctrl = no additional pretreatment; ATP = 
30 µM ATP pretreatment for 15 min; bleb: pretreatment with 100 µM blebbistatin for 30 min 
+  30 µM ATP for 15 min). All treatments were performed at RT. Scale bar = 20 µm. 
 
Figure 5. Pretreatment with a P2X7R specific antagonist (A-438079) results in 
abolishment of the protective effect induced by ATP. (A) HEKrtP2X7 cells pretreated with 
A-438079 (1 µM) for 15 min before the incubation with ATP (30 µM for 15 min) and SLO 
show a complete abolishment of the protective effect induced by ATP. N = 33, P<0.01. (B) 
Stimulation of HMC-1 cells with ATP (20 µM for 25 min) leads to improved resistance 
against SLO treatment (17.7% to 32.1% viability) and is abolished by pretreatment with A-
438079. All treatments were performed at RT. N = 43, t-test: P<0.01, asterisks denote 
significant differences. Data obtained by alamarBlue® viability assays. 
 
Figure 6. The role of blebbing as a non-immune defense mechanism. Blebbing provides 
spatially confined compartments in which membrane repair can take place (left cell). ATP 
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released from damaged cells serves as a paracrine signal, alerting neighbouring cells by 
activation of the P2X7R followed by blebbing (right cell).  
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